Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study.

Journal

ERJ open research

ISSN: 2312-0541

Titre abrégé: ERJ Open Res

Pays: England

ID NLM: 101671641

Informations de publication

Date de publication:
Jan 2022

Historique:

received: 05 07 2021

accepted: 27 09 2021

entrez: 10 3 2022

pubmed: 11 3 2022

medline: 11 3 2022

Statut: epublish

Résumé

Nutritional status impacts quality of life and prognosis of patients with respiratory diseases, including idiopathic pulmonary fibrosis (IPF). However, there is a lack of studies performing an extensive nutritional assessment of IPF patients. This study aimed to investigate the nutritional status and to identify nutritional phenotypes in a cohort of IPF patients at diagnosis. Patients underwent a thorough pulmonary and nutritional evaluation including questionnaires on nutritional status, and physical activity, anthropometry, body impedance, dynamometry, 4-m gait speed and blood tests. 90 IPF patients (78.9% males, mean age 72.7 years) were enrolled. The majority of patients were classified as Gender-Age-Physiology Index stage 2 (47, 52.2%) with an inactive lifestyle according to International Physical Activity Questionnaire score (39, 43.3%), and had mean forced vital capacity and diffusing capacity for carbon monoxide 86.5% and 54.2%, respectively. In regards to nutritional phenotypes, the majority of patients were normally nourished (67.8%, 95% CI 58.6-77.7%), followed by non-sarcopenic obese (25.3%, 95% CI 16.1-35.2%), sarcopenic (4.6%, 95% CI 0.0-14.5%) and sarcopenic obese (2.3%, 95% CI 0.0-12.2%). Among the normally nourished, 49.2% showed early signs of nutritional and physical performance alterations, including body mass index ≥30 kg·m IPF patients at diagnosis are mainly normally nourished and obese, but early signs of nutritional and physical performance impairment can already be identified at this stage.

Sections du résumé

Background UNASSIGNED

Methods UNASSIGNED

Patients underwent a thorough pulmonary and nutritional evaluation including questionnaires on nutritional status, and physical activity, anthropometry, body impedance, dynamometry, 4-m gait speed and blood tests.

Results UNASSIGNED

90 IPF patients (78.9% males, mean age 72.7 years) were enrolled. The majority of patients were classified as Gender-Age-Physiology Index stage 2 (47, 52.2%) with an inactive lifestyle according to International Physical Activity Questionnaire score (39, 43.3%), and had mean forced vital capacity and diffusing capacity for carbon monoxide 86.5% and 54.2%, respectively. In regards to nutritional phenotypes, the majority of patients were normally nourished (67.8%, 95% CI 58.6-77.7%), followed by non-sarcopenic obese (25.3%, 95% CI 16.1-35.2%), sarcopenic (4.6%, 95% CI 0.0-14.5%) and sarcopenic obese (2.3%, 95% CI 0.0-12.2%). Among the normally nourished, 49.2% showed early signs of nutritional and physical performance alterations, including body mass index ≥30 kg·m

Conclusions UNASSIGNED

IPF patients at diagnosis are mainly normally nourished and obese, but early signs of nutritional and physical performance impairment can already be identified at this stage.

Identifiants

DOI: 10.1183/23120541.00443-2021 PMID: 35265706 PMC: PMC8899499

pubmed: 35265706

doi: 10.1183/23120541.00443-2021

pii: 00443-2021

pmc: PMC8899499

pii:

doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Déclaration de conflit d'intérêts

Conflict of interest: P. Faverio reports personal fees from Boehringer Ingelheim and grants from Roche, outside the submitted work. Conflict of interest: A. Fumagalli has nothing to disclose. Conflict of interest: S. Conti has nothing to disclose. Conflict of interest: F. Madotto has nothing to disclose. Conflict of interest: F. Bini has nothing to disclose. Conflict of interest: S. Harari reports personal fees from Actelion, Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: M. Mondoni has nothing to disclose. Conflict of interest: T. Oggionni has nothing to disclose. Conflict of interest: E. Barisione reports personal fees from Chiesi Farmaceutici, Boehringer Ingelheim and GlaxoSmithKline, outside the submitted work. Conflict of interest: P. Ceruti has nothing to disclose. Conflict of interest: M.C. Papetti has nothing to disclose. Conflict of interest: B.D. Bodini has nothing to disclose. Conflict of interest: A. Caminati reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: A. Valentino has nothing to disclose. Conflict of interest: S. Centanni has nothing to disclose. Conflict of interest: D. Noè has nothing to disclose. Conflict of interest: M. Della Zoppa has nothing to disclose. Conflict of interest: S. Crotti has nothing to disclose. Conflict of interest: M. Grosso reports personal fees from Chiesi Farmaceutici and Johnson & Johnson, outside the submitted work. Conflict of interest: S.G. Sukkar has nothing to disclose. Conflict of interest: D. Modina has nothing to disclose. Conflict of interest: M. Andreoli has nothing to disclose. Conflict of interest: R. Nicali has nothing to disclose. Conflict of interest: G. Suigo has nothing to disclose. Conflict of interest: F. De Giacomi has nothing to disclose. Conflict of interest: S. Busnelli has nothing to disclose. Conflict of interest: E. Cattaneo has nothing to disclose. Conflict of interest: L.G. Mantovani has nothing to disclose. Conflict of interest: G. Cesana has nothing to disclose. Conflict of interest: A. Pesci has nothing to disclose. Conflict of interest: F. Luppi reports lectures fee from Roche and from Boehringer Ingelheim.

Références

Clin Nutr. 2010 Feb;29(1):65-71

pubmed: 19695747

Eur Respir J. 2014 Dec;44(6):1504-20

pubmed: 25234804

J Gerontol A Biol Sci Med Sci. 2014 May;69(5):559-66

pubmed: 24737558

Nutrition. 2019 Jun;62:115-121

pubmed: 30878815

Adv Exp Med Biol. 2015;840:45-9

pubmed: 25310942

Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68

pubmed: 30168753

Respirology. 2017 Apr;22(3):480-485

pubmed: 27868303

Int J Obes Relat Metab Disord. 1998 Feb;22(2):97-104

pubmed: 9504317

Eur Respir J. 2012 Dec;40(6):1324-43

pubmed: 22743675

Age Ageing. 2014 Jul;43(4):548-53

pubmed: 24366838

Respir Res. 2020 Nov 25;21(1):312

pubmed: 33239000

Eur Respir J. 2014 Dec;44(6):1428-46

pubmed: 25359355

Age Ageing. 2011 Jul;40(4):423-9

pubmed: 21624928

Arch Intern Med. 2004 Mar 8;164(5):551-6

pubmed: 15006833

PLoS Med. 2007 Oct 16;4(10):e296

pubmed: 17941714

Respir Res. 2018 Feb 22;19(1):32

pubmed: 29471816

PLoS One. 2016 Feb 03;11(2):e0147072

pubmed: 26841042

Chest. 2009 Apr;135(4):929-935

pubmed: 19017875

Chest. 2007 May;131(5):1448-53

pubmed: 17400656

Respir Med. 2010 Jul;104(7):1035-41

pubmed: 20199856

BMC Pulm Med. 2021 Feb 5;21(1):51

pubmed: 33546667

Clin Nutr. 2008 Dec;27(6):793-9

pubmed: 18718696

Pulm Pharmacol Ther. 2019 Apr;55:17-24

pubmed: 30659895

Nutrients. 2020 Apr 17;12(4):

pubmed: 32316662

Eur Respir J. 2017 Jan 3;49(1):

pubmed: 28049168

Respirology. 2021 Feb;26(2):171-179

pubmed: 32969124

Respiration. 2018;96(4):338-347

pubmed: 30130749

Eur Respir J. 2019 Feb 7;53(2):

pubmed: 30487200

Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88

pubmed: 31613151